Journal
JOURNAL OF LAW MEDICINE & ETHICS
Volume 42, Issue -, Pages 22-41Publisher
SAGE PUBLICATIONS INC
DOI: 10.1111/jlme.12160
Keywords
-
Categories
Funding
- NHGRI NIH HHS [R01 HG006460] Funding Source: Medline
Ask authors/readers for more resources
Public and private payers face complex decisions regarding whether, when, and how to cover and reimburse for next generation sequencing (NGS)-based tests. Yet a predictable reimbursement pathway is critical both for patient access and incentives to provide the market with better clinical evidence. While preliminary data suggests that payers will use similar evidentiary standards as those used to evaluate established molecular diagnostic tests, the volume and complexity of information generated by NGS raises a host of additional considerations for payers that are specific to this technology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available